Purple Biotech: Does The Cash Really Get IM1240 Into The Clinic?
Purple ended 2025 with $9.6 million in cash and deposits, but roughly $0.9 million of that sits in pledged short-term deposits. That looks sufficient to get IM1240 through GLP tox, an IND filing, and first-patient dosing, but it does not look like a comfortable buffer beyond that proof bridge.
What The Cash Actually Buys
The main article argued that Purple’s cash mainly buys time for IM1240. This follow-up isolates the most concrete part of that claim: how much time the reported $9.6 million really buys, and what is actually included in that promise.
What has improved should be stated upfront. In January 2026, the company reported an important toxicology milestone for IM1240, with improved safety at doses up to 300 times higher than a non-capped comparator, minimal cytokine release, higher systemic exposure, and a prolonged half-life. By March 2026, the corporate presentation had already translated that scientific progress into an operating roadmap: GLP tox in Q3 2026, IND submission in Q4 2026, and Phase 1 start in Q1 2027, including first-patient dosing.
That is exactly where the discussion has to move from science to cash. The presentation does not say the current balance funds a full clinical program or an early clinical readout. It says something much narrower: runway into H1 2027, covering IM1240 tox, IND filing up to Phase 1 initiation. That wording matters. The company is not presenting a runway to data. It is presenting a bridge to the point where the program enters the clinic.
The right framing here is all-in cash flexibility. In a pre-revenue biotech, there is no meaningful “normalized” cash generation to lean on. The question is how much cash is really available, how much of it is actually flexible, and which milestones it must fund before cash becomes the issue again.
What Is Really Left From The $9.6 Million
The official year-end headline is $9.574 million in cash, cash equivalents, and short-term deposits. But the breakdown matters more than the headline:
| Layer | USD million | Why it matters |
|---|---|---|
| Cash, cash equivalents, and short-term deposits | 9.574 | The broad liquidity number the company highlights |
| Cash and cash equivalents | 8.717 | The more usable operating layer |
| Short-term deposits | 0.857 | Not the same as free operating cash |
| Of which, pledged for leases and credit | 0.157 | Cash tied to an existing operating framework |
| Of which, pledged for hedging transactions | 0.700 | Cash that does not fully sit at IM1240’s disposal |
| Current lease liability | 0.244 | Contractual cash use within 12 months |
| Financial debt | 0 | Helpful, but it does not create new runway |
| CAPEX commitments | 0 | Removes a non-program capital burden |
The point is not that pledged deposits disappear. They are still assets. But they do not provide the same flexibility as free cash when a company needs to fund GLP tox, an IND filing, and entry into Phase 1. That is why the more conservative working base is $8.7 million, not $9.6 million.
This also explains why the absence of debt is not the end of the story. Yes, the company has no borrowings and no CAPEX commitments. That helps. But no debt is not the same thing as surplus cash. In a pre-revenue biotech, the real question is not only what is missing from the balance sheet, but how much genuinely flexible cash is left once the less usable layers are filtered out.
What 2025 Burn Does And Does Not Say
In 2025, Purple used $5.7 million of cash in operating activities, versus $14.4 million in 2024. On the surface, that looks like a dramatic improvement. Research and development expense also fell to $3.7 million from $7.6 million. But the company itself explains why: the completion of CM24’s Phase 2 study in 2024 reduced clinical trial expense, and only part of that saving was offset by higher CMC activity.
That is a key point, because it means 2025 is not a “normal” IM1240 run rate on the road to the clinic. If anything, it is a transition year in which expensive clinical activity tied to an older asset fell away before the full cost of GLP tox, IND preparation, and Phase 1 initiation for IM1240 had fully come through.
That chart sharpens a point that the cash headline hides. Cash and deposits rose from $8.249 million to $9.574 million, but that happened because 2025 also brought in $6.3 million from financing activities, mainly from the September 2025 public offering and the ATM program. This is not a self-funding model. It is a model in which the capital markets bought the company more time.
There is also one small but important detail: as of March 18, 2026, the company had not sold any ADSs under the new ATM agreement signed in September 2025. So, as of the annual filing date, the bridge into H1 2027 still rested mainly on the year-end 2025 cash base, not on a post-balance-sheet funding reinforcement that had already happened.
On a straight-line basis, $8.7 million to $9.6 million against a $5.7 million annual operating burn can look like roughly 18 to 20 months of oxygen. That is misleading if taken at face value. The company’s own forward framing already assumes cash will have to cover GLP tox, the IND package, and the start of Phase 1. In other words, even if 2025 looks relatively comfortable, 2026 should be more expensive.
Mapping The Bridge To The Clinic
The right way to read the cash balance is against the milestones the company itself has published:
| Milestone | Timing | What is already supported today | What the cash bridge must cover |
|---|---|---|---|
| Toxicology milestone | January 2026 | Improved safety up to 300 times versus a non-capped comparator, lower cytokine release, higher systemic exposure, and a prolonged half-life | Completion of the advanced safety package and the move into GLP tox |
| GLP tox complete | Q3 2026 | The presentation defines this as the final safety studies supporting the IND filing | Completion of the safety package that underpins the IND |
| IND submission | Q4 2026 | The company presents this as the FDA application to begin human trials | Assembly of the regulatory package and transition to a clinical-stage asset |
| Phase 1 start, first patient dosed | Q1 2027 | This is the last step the company explicitly ties to the current runway | Trial opening and first-patient dosing, not clinical data |
That is why the most important sentence in the presentation is not “runway into 2027” but “up to Phase 1 initiation.” This is the language of a narrow proof bridge. It says the current cash is expected to get the program to human entry, not necessarily much beyond that.
The January 2026 toxicology update clearly strengthens the scientific side of the bridge. It did not just show better safety. It also provided a more favorable pharmacokinetic case, with higher systemic exposure and a longer half-life. That matters because it can improve dose selection and safety planning for the next stage. But stronger science does not cancel the fact that the next stages are also more expensive.
Where The Bridge Gets Tight
First: the broad $9.6 million headline is more generous than the cash that is really sitting at hand. About $0.857 million sits in short-term deposits serving as collateral, which is why the more flexible operating layer is $8.717 million.
Second: the 2025 burn was helped by the decline in CM24 clinical spending after Phase 2 completed. That makes it a soft base for reading 2026, the year in which IM1240 is supposed to go through GLP tox, IND submission, and Phase 1 start.
Third: the annual report itself leaves three possible levers for what comes next: out licensing, alternative financing arrangements, or lower spending. When a company is already listing those three tools at this stage, it is effectively saying the current bridge is not meant to carry the whole path beyond Phase 1 entry on its own.
Fourth: what is absent from the balance sheet, debt and CAPEX, actually sharpens the issue. This is not a classic leverage problem. It is a duration problem. The question is how far the current cash can push a program before additional capital or a partner becomes necessary.
Fifth: the March 2026 presentation itself chooses a conservative frame. It does not say “funded through Phase 1.” It says “funded through key milestones,” then spells out tox, IND filing, and up to Phase 1 initiation. That is not accidental wording. It marks the precise boundary of the confidence range management is willing to underwrite.
That is also where the practical conclusion comes from. The current cash position likely is enough to get IM1240 into the clinic. It does not look like a balance that already removes the question of post-dosing funding. If the timetable slips, if GLP tox or IND costs rise, or if Phase 1 requires a wider operating buffer than expected, the margin can close quickly.
Conclusion
The right read on Purple today is not “there is $9.6 million, so the financing issue is solved.” The right read is that the company bought itself a credible bridge to IM1240’s clinical entry point, but not much more than that.
Current thesis in one line: Purple’s current cash looks sufficient for IM1240’s GLP tox, IND submission, and Phase 1 initiation, but this is a narrow proof bridge, not a runway that comfortably covers the clinical phase beyond that point.
What changed most is that IM1240’s scientific file improved, and management has now published a clearer milestone map through early 2027. What did not change is that this remains a pre-revenue biotech whose cash position still depends on external financing and whose own filings already point to out licensing, alternative financing, or spending discipline as the next levers.
The strongest counter-thesis is that there is no immediate financing drama here: no debt, no CAPEX, at least 12 months of liquidity in the annual report, and a presentation that already speaks about runway into H1 2027. That is a serious argument. But even if one accepts it, it supports a bridge to Phase 1 initiation, not a cash cushion that makes the next financing question disappear.
So, over the next 2 to 4 quarters, the market will not only measure whether IM1240 advances scientifically. It will measure whether Purple can reach the IND and first-patient dosing without reopening the financing question earlier than expected.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.